Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy
| العنوان: | Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy |
|---|---|
| المؤلفون: | Stephanie Le Breton, Peter Baumgart, Andrzej Tykarski, Bernard Reimund, Philippe Ferber, Jaakko Tuomilehto |
| المصدر: | Blood Pressure. 17:15-23 |
| بيانات النشر: | Informa UK Limited, 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Combination therapy, Urology, Tetrazoles, Blood Pressure, 030204 cardiovascular system & hematology, Essential hypertension, law.invention, 03 medical and health sciences, 0302 clinical medicine, Hydrochlorothiazide, Double-Blind Method, Randomized controlled trial, law, Internal Medicine, medicine, Humans, 030212 general & internal medicine, Antihypertensive Agents, Aged, business.industry, Valine, General Medicine, Middle Aged, medicine.disease, 3. Good health, Blood pressure, Valsartan, Tolerability, Anesthesia, Hypertension, Valsartan/hydrochlorothiazide, Drug Therapy, Combination, Female, Cardiology and Cardiovascular Medicine, business, Angiotensin II Type 1 Receptor Blockers, medicine.drug |
| الوصف: | To investigate the efficacy and tolerability of valsartan (Val) 320 mg once daily (o.d.), Val/hydrochlorothiazide (HCTZ) 320/12.5 mg o.d. and Val/HCTZ 320/25 mg o.d. in patients with hypertension not adequately controlled by Val monotherapy.This double-blind, active-controlled, parallel-group, randomized trial recruited patientsor =18 years with mild-to-moderate essential hypertension, defined as mean sitting diastolic blood pressure (MSDBP) ofor =95 mmHg and110 mmHg without treatment. After washout, 3805 eligible patients received Val 320 mg o.d. single-blind for 4 weeks. Subsequently, patients with MSDBPor =90 and110 mmHg (n=2702) were randomized to double-blind treatment with Val 320 mg, Val/HCTZ 320/12.5 mg or Val/HCTZ 320/25 mg for 8 weeks. Mean changes in MSDBP and mean sitting systolic BP (MSSBP) from the start of the single-blind period were analysed, as well as the proportion of responders (MSDBP90 mmHg oror =10 mmHg decrease from the start of the double-blind period). Tolerability and safety were also assessed.Reductions in MSDBP and MSSBP were observed in all groups. Both combinations were associated with significantly greater reductions than monotherapy for MSDBP and MSSBP at Weeks 8 and 12 (all p0.0001). Both combinations also resulted in significantly greater proportion of responders at study end (74.9% and 68.8% for Val/HCTZ 320/25 mg and Val/HCTZ 320/12.5 mg, respectively) than monotherapy (52.7%; both p0.0001). In addition, a dose-response was observed with increasing dose of HCTZ with respect to MSSBP. All treatments were well tolerated.The combination ofVal and HCTZ at doses of 320/12.5 mg and 320/25 mg increases antihypertensive efficacy in patients with mild-to-moderate hypertension inadequately controlled with Val 320 mg monotherapy, without compromising tolerability. |
| تدمد: | 1651-1999 0803-7051 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2543ccf9879d26525705555d026961aTest https://doi.org/10.1080/08038020701832716Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....a2543ccf9879d26525705555d026961a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16511999 08037051 |
|---|